Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 117, Issue 3, Pages 549-556Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI30562
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA087879] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067665, R01HL066027] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055075] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA087879, CA87879] Funding Source: Medline
- NHLBI NIH HHS [HL03906, R01 HL066027, HL66027, P50 HL67665, HL087849, P50 HL067665] Funding Source: Medline
- NIAMS NIH HHS [R01 AR055075, AR 055075] Funding Source: Medline
Ask authors/readers for more resources
The CXC chemokine family is a pleiotropic family of cytokines that are involved in promoting the trafficking of various leukocytes, in regulating angiogenesis and vascular remodeling, and in promoting the mobilization and trafficking of mesenchymal progenitor cells such as fibrocytes. These functions of CXC chemokines are important in the pathogenesis of pulmonary fibrosis and other fibroproliferative disorders. In this Review, we discuss the biology of CXC chemokine family members, specifically as it relates to their role in regulating vascular remodeling and trafficking of circulating mesenchymal progenitor cells (also known as fibrocytes) in pulmonary fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
